{"id":13977,"date":"2011-09-28T08:11:59","date_gmt":"2011-09-28T12:11:59","guid":{"rendered":"http:\/\/1boringoldman.com\/?p=13977"},"modified":"2011-09-28T15:12:19","modified_gmt":"2011-09-28T19:12:19","slug":"echo-echo-echo-echo-echo-echo-echo","status":"publish","type":"post","link":"https:\/\/1boringoldman.com\/index.php\/2011\/09\/28\/echo-echo-echo-echo-echo-echo-echo\/","title":{"rendered":"echo<\/font> echo echo<\/font> echo<\/font> echo<\/font> echo<\/font> echo…<\/font>"},"content":{"rendered":"
<\/div>\n

Some echos just keep on reverberating, maybe until the end of days. I reckon the Atypicals<\/em> are iterating towards becoming the Typicals<\/em>, at least from the perspective of the F.D.A. [so much for there being a rule about there being a need before a new drug is introduced to the market]. But in psychopharmacology, making it onto the shelves is just the first step. After that, there’s a  secondary<\/em> pipeline <\/em>– the indication march… <\/p>\n

<\/p>\n

Latuda<\/font>®<\/sup><\/font><\/strong> has a rich tradition of Clinical Trials and marketing techniques to lead them on their journey. The first part was the hardest – getting on the board. That’s behind them now: <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Sunovion<\/font><\/strong>®<\/sup><\/font><\/strong><\/em> Latuda <\/font><\/strong>Schizophrenia Clinical Trials<\/font><\/strong><\/td>\n<\/tr>\n
NCT ID<\/sup><\/font><\/strong><\/td>\nRecruit<\/sup><\/font><\/strong><\/td>\nPhase<\/sup><\/font><\/strong><\/td>\nStartDate<\/sup><\/font><\/strong><\/td>\n<\/tr>\n
\n
<\/td>\n<\/tr>\n
NCT01074073<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nI<\/sup><\/td>\n08\/2008<\/sup><\/td>\n<\/tr>\n
NCT01082250<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nI<\/sup><\/td>\n07\/2008<\/sup><\/td>\n<\/tr>\n
NCT01074632<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nI<\/sup><\/td>\n05\/2009<\/sup><\/td>\n<\/tr>\n
NCT01082263<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nI<\/sup><\/td>\n10\/2008<\/sup><\/td>\n<\/tr>\n
NCT01082289<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nI<\/sup><\/td>\n09\/2008<\/sup><\/td>\n<\/tr>\n
NCT00044005<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nII<\/sup><\/td>\n09\/2002<\/sup><\/td>\n<\/tr>\n
NCT00088621<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nII<\/sup><\/td>\n07\/2004<\/sup><\/td>\n<\/tr>\n
NCT00044044<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nII<\/sup><\/td>\n07\/2002<\/sup><\/td>\n<\/tr>\n
NCT00088634<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nII<\/sup><\/td>\n05\/2004<\/sup><\/td>\n<\/tr>\n
NCT01435928<\/font><\/a><\/sup><\/strong><\/td>\nNot Yet<\/sup><\/td>\nIII<\/sup><\/td>\n09\/2011<\/sup><\/td>\n<\/tr>\n
NCT00790192<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nIII<\/sup><\/td>\n10\/2008<\/sup><\/td>\n<\/tr>\n
NCT00549718<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nIII<\/sup><\/td>\n10\/2007<\/sup><\/td>\n<\/tr>\n
NCT00641745<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nIII<\/sup><\/td>\n03\/2008<\/sup><\/td>\n<\/tr>\n
NCT00615433<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nIII<\/sup><\/td>\n01\/2008<\/sup><\/td>\n<\/tr>\n
NCT01143090<\/font><\/a><\/sup><\/strong><\/td>\nActive<\/sup><\/td>\nIII<\/sup><\/td>\n08\/2010<\/sup><\/td>\n<\/tr>\n
NCT01143077<\/font><\/a><\/sup><\/strong><\/td>\nDone<\/sup><\/td>\nIII<\/sup><\/td>\n06\/2010<\/sup><\/td>\n<\/tr>\n
NCT00711269<\/font><\/a><\/sup><\/strong><\/td>\nYES<\/sup><\/td>\nIII<\/sup><\/td>\n07\/2008<\/sup><\/td>\n<\/tr>\n<\/table>\n

Now comes the indication march proper [already in place well before the initial F.D.A. Approval]: <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n<\/table>\n

<\/p>\n

They’re following in the footsteps of some of the greats, well warned about the shoals of false advertising and other sleaze by the antics of their predecessors. Their problem – the generics are here. Even just plain Seroquel went off-patent this week<\/font><\/strong><\/u><\/a> – so, at $14+\/pill for Latuda<\/font><\/strong>, it’s going to be an uphill climb. What they have going for them is that it seems to be weight neutral [so far]. What’s on the downside? It’s a decidedly weak sister [efficacy-wise]; it has an annoying EPS profile; and maybe, just maybe, people are finally tired of over-medicating and being over-medicated. But at Sunovion<\/font><\/strong>, hope springs eternal<\/font><\/strong><\/u><\/a>…<\/div>\n
Soulful Sepulcher<\/font><\/strong><\/u><\/a>… <\/div>\n","protected":false},"excerpt":{"rendered":"

Some echos just keep on reverberating, maybe until the end of days. I reckon the Atypicals are iterating towards becoming the Typicals, at least from the perspective of the F.D.A. [so much for there being a rule about there being a need before a new drug is introduced to the market]. But in psychopharmacology, making […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_bbp_topic_count":0,"_bbp_reply_count":0,"_bbp_total_topic_count":0,"_bbp_total_reply_count":0,"_bbp_voice_count":0,"_bbp_anonymous_reply_count":0,"_bbp_forum_subforum_count":0,"footnotes":""},"categories":[2],"tags":[],"class_list":["post-13977","post","type-post","status-publish","format-standard","hentry","category-politics"],"_links":{"self":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/13977","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/comments?post=13977"}],"version-history":[{"count":85,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/13977\/revisions"}],"predecessor-version":[{"id":14064,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/posts\/13977\/revisions\/14064"}],"wp:attachment":[{"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/media?parent=13977"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/categories?post=13977"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/1boringoldman.com\/index.php\/wp-json\/wp\/v2\/tags?post=13977"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}

Sunovion<\/font><\/strong>®<\/sup><\/font><\/strong><\/em> Latuda <\/font><\/strong>Phase III Clinical Trials<\/font><\/strong><\/td>\n<\/tr>\n
NCT ID<\/sup><\/font><\/strong><\/td>\nTitle<\/sup><\/font><\/strong><\/td>\nRecruit<\/sup><\/font><\/strong><\/td>\nStartDate<\/sup><\/font><\/strong><\/td>\n<\/tr>\n
\n
<\/td>\n<\/tr>\n
NCT00868699<\/sup><\/font><\/strong><\/a><\/td>\n6-week Study, Bipolar I Depression (Monotherapy)<\/sup><\/td>\nYES<\/sup><\/td>\n04\/2009<\/sup><\/td>\n<\/tr>\n
NCT00868959<\/sup><\/font><\/strong><\/a><\/td>\n24-week Extension Study, Bipolar I Depression<\/sup><\/td>\nYES<\/sup><\/td>\n04\/2009<\/sup><\/td>\n<\/tr>\n
NCT00868452<\/sup><\/font><\/strong><\/a><\/td>\n6-week Study, Bipolar I Depression (Add-on)<\/sup><\/td>\nYES<\/sup><\/td>\n04\/2009<\/sup><\/td>\n<\/tr>\n
NCT01284517<\/sup><\/font><\/strong><\/a><\/td>\n6-week Study, Bipolar I Depression<\/sup><\/td>\nYES<\/sup><\/td>\n11\/2010<\/sup><\/td>\n<\/tr>\n
NCT01358357<\/sup><\/font><\/strong><\/a><\/td>\nBipolar Maintenance Adjunctive to Lithium or Divalproex<\/sup><\/td>\nYES<\/sup><\/td>\n06\/2011<\/sup><\/td>\n<\/tr>\n
NCT01421134<\/sup><\/font><\/strong><\/a><\/td>\nMDD With Mixed Features – Flexible Dose<\/sup><\/td>\nYES<\/sup><\/td>\n09\/2011<\/sup><\/td>\n<\/tr>\n
NCT01423253<\/sup><\/font><\/strong><\/a><\/td>\nMDD With Mixed Features – Extension<\/sup><\/td>\nNot Yet<\/sup><\/td>\n09\/2011<\/sup><\/td>\n<\/tr>\n
NCT01423240<\/sup><\/font><\/strong><\/a><\/td>\nMDD With Mixed Features<\/sup><\/td>\nNot Yet<\/sup><\/td>\n10\/2011<\/sup><\/td>\n<\/tr>\n